ArticleBMC endocrine disorders2025
Dysregulation of miR-302a-3p in diabetic nephropathy and its role in inflammatory response.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research aims to reveal the regulatory mechanism of miR-302a-3p in diabetic nephropathy (DN) and its role in inflammatory responses.
methodsSerum samples were collected from DN patients and healthy controls, and RT-qPCR was employed to determine miR-302a-3p expression levels. The diagnostic value of this molecule in DN was evaluated through the receiver operating characteristic curve. A high-glucose condition was induced in HK-2 cells to establish an in vitro cell model. CCK-8 and flow cytometry were used to assess cell viability and apoptosis changes. ELISA was used to detect the levels of inflammatory factors, and the ROS assay kit was used to assess the level of ROS. The dual-luciferase reporter assay confirmed the targeted binding relationship between miR-302a-3p and FGF-16. Functional rescue experiments were conducted by knocking down FGF-16.
resultsThe level of miR-302a-3p in the serum of patients with DN was significantly increased, and its area under the curve (AUC) for diagnosing DN was 0.9168. High glucose induced an upregulation of miR-302a-3p in HK-2 cells. Inhibiting miR-302a-3p significantly reversed high glucose-induced cell apoptosis and release of ROS and pro-inflammatory factors. miR-302a-3p directly targets and inhibits FGF-16. In HK-2 cells induced by high glucose, knocking down FGF-16 would eliminate the protective effect of miR-302a-3p inhibitor on the cells.
conclusionsmiR-302a-3p enhances inflammatory response, oxidative stress and cell apoptosis by targeting and inhibiting FGF-16, thereby promoting renal tubular damage in DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.